MBiotech Program News
13/07/2010 - 10:00 -
Part II: Subsequent entry biologics: Biosame or biodifferent?
MBiotech alumna Eva Furczon and Associate Director Leigh Revers recognized a need for today's generation of pharmacists to become better informed about the history of biologics and to learn how they differ from the more conventional small-molecule drugs that are prevalent in pharmacopeias.
...
09/06/2010 - 10:00 -
An introduction to biologics and biosimilars. Part I: Biologics: What are they and where do they come from?
Eva Furczon, a Master of Biotechnology student at the University of Toronto, and an intern at Roche Canada co-authored a paper with Associate Director Leigh Revers. The publication recently appeared in the 'Canadian Pharmacists Journal" (CPJRPC).
"An Introduction to Biologics" is a...
26/03/2010 - 10:00 -
MBiotech Associate Director, Leigh Revers, publishes a leading article in Molecular Cancer, a peer-reviewed journal specializing in new oncology research
The article is the culmination of an extensive research program begun at Princess Margaret Hospital in 2000. The work, which focuses on the advancement of novel toxin-based biologic compounds as the next wave of specific anti-cancer therapeutics led Drs. Revers and Gariépy (currently a Senior Scientist at the Sunnybrook Research Institute)...
04/03/2010 - 10:26 -
MBiotech Director published in 'Nature'
MBiotech Director published in 'Nature'
Mar 04, 2010
Scott Prosser, Director of the MBiotech Program, publishes in 'Nature', one of the top two leading scientific journals in the world!
Dr. Prosser and colleagues investigate a class of receptors called G-coupled protein receptors which constitutes the vast...
25/11/2009 - 10:28 -
U of T Mississauga to offer biotechnology program for newcomers to Canada
The University of Toronto Mississauga, in partnership with U of T's School of Continuing Studies and AstraZeneca Canada Inc., will offer a program in biotechnology for internationally trained professionals, beginning in January 2010.
On Nov. 25 at AstraZeneca Canada Inc, the provincial government announced $2.5 million to fund the new...